Akkermansia vs Ozempic: Why Gut Balance May Shape GLP-1 and Digestion

The GLP-1 Revolution: What Is Really Happening Inside Your Body

Medications like Ozempic and Wegovy have reshaped how doctors and patients approach type 2 diabetes and obesity. They are effective, well-studied prescription drugs, and for many people they deliver meaningful improvements in blood sugar and body weight. This article is not about replacing them. It is about something quieter that sits alongside them: the gut environment those drugs act in, and the trillions of bacteria that help shape it.

As a microbiome scientist, I find the overlap between GLP-1 biology and the gut microbiome genuinely interesting, and I also want to be careful about what the evidence does and does not show. So this article looks at how GLP-1 medications change digestion, why they so often cause gut side effects, and where microbiome support may reasonably fit as a complement to treatment, not a substitute for it.

Quick Answer: Can Akkermansia or Gut Support Replace or Boost GLP-1 Drugs?

No supplement replaces a GLP-1 medication, and you should not treat one as an alternative. On boosting the drug, the honest answer is that it is an interesting possibility rather than a proven effect. There is real science linking the gut bacterium Akkermansia muciniphila to the GLP-1 pathway, but most of it is from animal and cell studies, with only early human data. Where gut support has a more reasonable, everyday role is in tolerability: GLP-1 drugs commonly cause gut side effects like constipation and bloating, and a fibre-rich diet and a healthy microbiome may help you feel better during treatment and support your metabolic health overall. Think of it as caring for the environment the medication works in, alongside your prescriber's plan, not as a way to do without the medication or to make it work harder.

What This Page Is and Is Not Saying

How GLP-1 Medications Change Your Digestive System

First, a point of accuracy that matters on a page like this. These medications are not all the same class. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist, meaning it mimics the natural hormone glucagon-like peptide-1. Tirzepatide (Mounjaro, Zepbound) is a dual agonist that acts on both the GIP and GLP-1 receptors, a related but distinct mechanism. All of them reduce appetite, slow how quickly the stomach empties, and improve blood sugar regulation, but it is worth being precise about which drug does what.

The link between gastric emptying, the blood sugar response after meals, and incretin hormones like GLP-1 is tightly interconnected. Research in Diabetes Care by Marathe and colleagues showed that altering the rate of gastric emptying directly affects metabolic signaling, including insulin secretion and glucose absorption (Marathe et al., 2013). When these medications slow that process, the effects are widespread: food moves more slowly, nutrient absorption patterns change, and the feedback loops between gut and brain are recalibrated. For most people this is part of how the drug works. For a significant number, it also comes with digestive discomfort (Drucker, 2024).

For a deeper breakdown of GLP-1 gut side effects, see: "GLP-1 Side Effects and Gut Health."

When Slowed Digestion Shifts Microbial Balance

Many people on GLP-1 medications report bloating, constipation, and a general feeling of digestive sluggishness. These are a recognized and common effect of how the medication changes gut motility, not something random, though how strongly any one person is affected varies.

When gastric emptying slows, the environment inside the gut changes. Food spends more time fermenting, gas production can increase, and the balance of bacteria that thrive in a slower-moving gut may shift. Over time this could change the composition of the microbiome, though the size and lasting nature of that shift in people is still being studied.

There is also an intriguing reverse direction. Research in Cell Metabolism by Grasset and colleagues showed that, in diabetic mice, a particular form of gut dysbiosis induced resistance to GLP-1's effects through gut-brain axis mechanisms (Grasset et al., 2017). This is a mouse study, so it should be read as a hypothesis-generating finding rather than proof about people, but it raises a reasonable question: the state of the gut may influence how well GLP-1 signaling works, and the relationship may run in both directions.

To learn more about how your digestive system connects to broader metabolic health, see "Digestive Wellness Explained: More Than Just Digestion."

The Microbiome Plays a Larger Role Than You Think

Your gut microbiome is not just a passive collection of bacteria. It is an active system that influences appetite signaling, communication between the gut and brain, inflammation, and energy balance. When researchers study metabolic health, they increasingly find the microbiome is not merely correlated with outcomes but mechanistically involved in producing them. At the center of much of this work is one bacterium that has drawn growing attention over the past decade: Akkermansia muciniphila.

Akkermansia muciniphila and Metabolic Health

Akkermansia muciniphila lives mainly in the mucus layer lining the intestine, where it helps maintain that lining, interacts with the immune system, and supports metabolic processes. The research on it is genuinely interesting, and it is worth being clear about which findings come from animals and which from people.

A landmark study in PNAS showed that Akkermansia interacts directly with the intestinal epithelium and that, in mice, administering it reversed key features of diet-induced obesity, including fat mass gain, metabolic inflammation, and gut barrier disruption (Everard et al., 2013). This is animal evidence, and an influential piece of it, but animal evidence.

Human data builds on this. A proof-of-concept trial in Nature Medicine found that supplementation with a pasteurized form of Akkermansia in overweight and obese volunteers was safe, well tolerated, and associated with improvements in several metabolic markers, including insulin sensitivity and blood lipids (Depommier et al., 2019). It is an encouraging result, and it is small and exploratory, in 32 people who completed the study, using a pasteurized preparation.

Most relevant to the GLP-1 conversation, a 2021 study in Nature Microbiology identified a protein secreted by Akkermansia, called P9, that stimulates GLP-1 release from intestinal L-cells by binding a receptor called ICAM-2 (Yoon et al., 2021). It is a concrete molecular mechanism linking this bacterium to the same hormone pathway GLP-1 drugs target, and it was demonstrated in mice and cultured cells. Whether it translates into a meaningful effect in people is not yet known.

 To learn more, see "Akkermansia Muciniphila and the Full Microbiota Ecosystem."

How a GLP-1 Medication and Gut Support Play Different Roles

These are not two versions of the same thing. One is a prescription treatment; the other is background support for the environment it works in.

Note: Gut or Akkermansia support is not a replacement for prescribed GLP-1 medication. Talk to your healthcare provider before making any change to your treatment plan.

Where a Supplement Fits, and Where It Does Not

Diet and lifestyle come first, and no supplement is a substitute for your prescribed treatment. If, after that, you and your clinician think a targeted microbiome supplement is worth trying for comfort and general gut support, Next-Microbiome makes two relevant options. Akkermansia Chewable is built around Akkermansia muciniphila, the mucus-associated species discussed above. Boost Synergy pairs Akkermansia with Clostridium butyricum, a butyrate producer, aimed at broader short-chain-fatty-acid support. Treat either as optional support for the gut environment during metabolic care, not as something that acts on the drug or replaces it, and clear it with your doctor or pharmacist first if you are on a GLP-1 medication.

Who Might Consider This Approach

Gut-focused support may be particularly relevant for people experiencing digestive side effects from GLP-1 medications who want to feel more comfortable during treatment. It may also appeal to people focused on long-term metabolic health who want to support the systems underlying healthy weight and blood sugar regulation. And for anyone with a sensitive gut who has struggled with digestive changes when starting new medications, gentle, food-first support is a proactive rather than reactive strategy.

To be clear once more: this is not about replacing prescribed treatment. It is about supporting the environment in which that treatment operates, so your body can adapt more comfortably, and it should be done in coordination with your care team.

The Direction of Metabolic Medicine

The broader trajectory of metabolic medicine is shifting from a model that relies solely on pharmacology toward one that also considers the internal ecosystem those interventions operate in. GLP-1 drugs are powerful, well-validated tools. The microbiome, and bacteria like Akkermansia muciniphila, may help shape the environment in which GLP-1 signaling takes place. Supporting that environment through diet and lifestyle is a reasonable, low-risk thing to do for long-term metabolic health, whether or not you are on GLP-1 therapy, and it complements medical care rather than competing with it.

Common Questions About GLP-1, Akkermansia, and Gut Health

1. What does Akkermansia do for your body?

Akkermansia muciniphila is a gut bacterium that lives in the mucus layer of the intestine. It feeds on mucin and, in doing so, helps stimulate renewal of the mucus lining, which supports the gut barrier. Research has associated it with lower intestinal inflammation and better metabolic markers. In animal studies, giving Akkermansia reversed several features of diet-induced metabolic dysfunction, and a small human proof-of-concept trial found that a pasteurized form was safe and linked to metabolic improvements. Researchers have also identified a protein it makes, called P9, that stimulates GLP-1 release in laboratory and animal studies.

2. Does Akkermansia help metabolism?

It may play a supportive role. In animal models, it has been linked to reduced fat gain, better insulin sensitivity, and lower metabolic inflammation, largely by strengthening the gut barrier and limiting the leakage of inflammatory compounds. In a small human trial, a pasteurized form was associated with improved insulin sensitivity and blood lipids. It is worth being clear that most of the strongest evidence is still from animal studies, and larger human trials are needed. Check with your healthcare provider before using Akkermansia supplements for metabolic support.

3. Does Akkermansia stimulate GLP-1?

In laboratory and animal research, yes. A 2021 Nature Microbiology study found that an Akkermansia protein called P9 triggers GLP-1 release from intestinal L-cells in mice by activating the ICAM-2 receptor, and the bacterium's metabolite propionate can also stimulate GLP-1. A 2025 cell study found Akkermansia extracts increased GLP-1 secretion from human L-cells in vitro. These findings are compelling mechanistically, but they come from animal and cell models, so a meaningful effect in people is not yet confirmed.

4. Should you take probiotics with GLP-1?

There is no blanket yes or no, and it depends on the specific product and your situation. Broad-spectrum probiotics may not address the particular shifts GLP-1 therapy causes, and some could worsen bloating in a gut already moving more slowly. Strains studied in metabolic contexts may be more relevant, but the key point is to choose carefully and, most importantly, to check with your healthcare provider before adding any supplement while on a GLP-1 medication, since responses vary and the supplement needs to fit your overall care.

5. How to increase GLP-1 in the gut?

GLP-1 is made by L-cells in the intestinal lining, and several everyday factors support its natural release. Meals with protein, healthy fats, and fibre can stimulate L-cell activity. Prebiotic fibres and polyphenol-rich foods like berries and green tea support beneficial gut bacteria. Fermented foods add diversity, which is generally linked to better metabolic signaling. Some research suggests meal timing may play a role, though results are mixed. None of this is a substitute for medical treatment, but a microbiome-supportive diet is a sound foundation for metabolic health.

Scientific References 

1. Marathe CS, Rayner CK, Jones KL, Horowitz M.
   Relationships between gastric emptying, postprandial glycemia, and incretin hormones
   Diabetes Care 2013;36(5):1396-1405
   doi:10.2337/dc12-1609 (Human physiology review)

2. Drucker DJ.
   Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity
   Diabetes Care 2024;47(11):1873-1888
   doi:10.2337/dci24-0003 (Review)

3. Grasset E, Puel A, Charpentier J, et al.
   A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism
   Cell Metab 2017;25(5):1075-1090.e5 
   doi:10.1016/j.cmet.2017.04.013 (Animal study, mice)

4. Everard A, Belzer C, Geurts L, et al.
   Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
   Proc Natl Acad Sci USA 2013;110(22):9066-9071 
   doi:10.1073/pnas.1219451110 (Animal study, mice)

5. Depommier C, Everard A, Druart C, et al.
   Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
   Nat Med 2019;25(7):1096-1103  
   doi:10.1038/s41591-019-0495-2 (Human pilot study, pasteurized form, 32 completers)

6. Yoon HS, Cho CH, Yun MS, et al.
   Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
   Nat Microbiol 2021;6(5):563-573 
   doi:10.1038/s41564-021-00880-5 (Animal and cell study; the P9 protein)

Related Reading

• Akkermansia muciniphila: Benefits, Science, and Its Role in Gut Health, on the bacterium itself.

• Gut Barrier Science Hub: Intestinal Permeability and Leaky Gut, on the gut lining and metabolic signaling.

• Best Probiotic for Leaky Gut: A Science-Based Gut Barrier Guide, on choosing a probiotic for barrier support.

• The Gut-Brain Axis: How Microbes Shape Mood, Stress, and Appetite, on appetite and gut-brain signaling.

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions

• Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

Active Ulcerative Colitis (Inflammatory Bowel Disease)

Hyperoxaluria (Oxalate Metabolism Disorder)

Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Review and Sources

This article is written and reviewed by a microbiome scientist and is based on the peer-reviewed studies listed in the References. Because it touches on prescription medications, it is written to describe possible mechanisms and supportive strategies without suggesting that any supplement can replace medical treatment, and it labels animal and cell evidence as such. It is reviewed periodically against current research.

Medical Disclaimer

This content is for educational and informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are prescription drugs. Do not start, stop, change, or delay any medication, and do not delay seeking medical care, based on anything in this article. No dietary supplement is a substitute for prescribed treatment. Talk to your prescriber, doctor, or pharmacist before adding any probiotic or supplement while on a GLP-1 medication. Dietary supplements are not reviewed or approved by the US Food and Drug Administration for safety before they are sold, and products containing Akkermansia muciniphila are intended for adults; the international regulatory clearances that exist cover adults and adolescents aged 12 and over. Consult a qualified healthcare professional for individual health decisions, especially if you are pregnant, nursing, immunocompromised, managing a health condition, or taking medication.

Last reviewed: July 2026